【佳學(xué)基因檢測(cè)】CCDC137表達(dá)的預(yù)后意義及其與肝細(xì)胞癌免疫浸潤(rùn)的關(guān)系

上海腫瘤基因檢測(cè)機(jī)構(gòu)機(jī)會(huì)

參加學(xué)術(shù)會(huì)議時(shí)了解《Dis Markers》在.?2022 Aug 24;2022:5638675.發(fā)表了一篇題目為《CCDC137表達(dá)的預(yù)后意義及其與肝細(xì)胞癌免疫浸潤(rùn)的關(guān)系》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Lu Bai,?Zhao-Xu Yang,?Jian-Shan Liu,?De-Sheng Wang,?Heng-Chao Yu?等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

在全球范圍內(nèi)，肝細(xì)胞癌 (HCC) 是癌癥相關(guān)死亡的賊常見(jiàn)原因之一。由于遠(yuǎn)處轉(zhuǎn)移和反復(fù)，HCC患者的臨床結(jié)果仍然很差。近年來(lái)，越來(lái)越多的證據(jù)證實(shí)含有卷曲螺旋結(jié)構(gòu)域（CCDC）的家族蛋白參與了多種疾病的進(jìn)展。然而，尚未研究包含卷曲螺旋結(jié)構(gòu)域的 137 (CCDC137) 在肝細(xì)胞癌 (HCC) 中的表達(dá)和臨床意義。在 TCGA-LIHC 中獲得了 3 級(jí) mRNA 表達(dá)譜和臨床病理學(xué)數(shù)據(jù)。在 371 個(gè) HCC 和 50 個(gè)非腫瘤樣本之間篩選了差異表達(dá)基因 (DEG)。在 HCC 患者中分析了 CCDC137 的預(yù)后價(jià)值。研究了 CCDC137 與癌癥免疫浸潤(rùn)之間的相關(guān)性。本研究共獲得2897個(gè)DEG：2451個(gè)基因顯著上調(diào)，446個(gè)基因顯著下調(diào)。 KEGG 分析顯示這些 DEG 參與了腫瘤進(jìn)展。在 2897 個(gè) DEG 中，我們發(fā)現(xiàn)與非腫瘤標(biāo)本相比，HCC 標(biāo)本中 CCDC137 的表達(dá)明顯增加。高水平的 CCDC137 表達(dá)與晚期腫瘤分期和分級(jí)有關(guān)。此外，與 CCDC137 水平較低的患者相比，CCDC137 表達(dá)水平較高的患者的總生存期和無(wú)病生存期較短。 CCDC137 表達(dá)與幾種免疫細(xì)胞的浸潤(rùn)水平呈正相關(guān)，例如 CD8 T 細(xì)胞和 Th2 細(xì)胞。賊后，體外實(shí)驗(yàn)證實(shí)CCDC137在HCC細(xì)胞中高表達(dá)，其敲低抑制了HCC細(xì)胞的增殖。總之，我們的研究結(jié)果表明，CCDC137 可用作 HCC 免疫浸潤(rùn)和預(yù)后不良的生物標(biāo)志物，這為 HCC 的潛在療法提供了新的見(jiàn)解。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

Globally, hepatocellular carcinoma (HCC) is one of the most common causes of cancer-associated mortalities. The clinical outcome of HCC patients remains poor due to distant metastasis and recurrence. In recent years, growing evidences have confirmed that the coiled-coil domain-containing (CCDC) family proteins are involved in the progression of several diseases. However, the expression and clinical significance of the coiled-coil domain-containing 137 (CCDC137) in hepatocellular carcinoma (HCC) have not been investigated. Level 3 mRNA expression profiles and clinicopathological data were obtained in TCGA-LIHC. Differentially expressed genes (DEGs) were screened between 371 HCC and 50 nontumor specimens. The prognostic value of CCDC137 was analyzed in HCC patients. The correlations between CCDC137 and cancer immune infiltrates were investigated. In this study, a total of 2897 DEGs were obtained: 2451 genes were significantly upregulated and 446 genes were significantly downregulated. KEGG assays revealed that these DEGs were involved in tumor progression. Among 2897 DEGs, we found that CCDC137 expression was distinctly increased in HCC specimens compared with nontumor specimens. A high level of CCDC137 expression was related to an advanced tumor stage and grade. Moreover, patients with higher levels of CCDC137 expression had a shorter overall survival and disease-free survival than patients with lower CCDC137 levels. CCDC137 expression was positively correlated with infiltrating levels of several immune cells, such as CD8 T cells and Th2 cells. Finally, in vitro experiments confirmed that CCDC137 expression was highly expressed in HCC cells, and its knockdown suppressed the proliferation of HCC cells. Taken together, our findings revealed that CCDC137 might be used as a biomarker for immune infiltration and poor prognosis in HCC, which offered fresh insight on potential therapies for HCC.